Switch theme
Sign up to access all valuation multiples
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
1981
13
LTM Revenue $35.8M
LTM EBITDA -$4.4M
$320M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
XOMA Royalty has a last 12-month revenue (LTM) of $35.8M and a last 12-month EBITDA of -$4.4M.
In the most recent fiscal year, XOMA Royalty achieved revenue of $10.2M and an EBITDA of -$5.4M.
XOMA Royalty expects next 12-month revenue of XXX and NTM EBITDA of XXX
See XOMA Royalty valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $35.8M | XXX | $10.2M | XXX | XXX | XXX |
| Gross Profit | $35.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$4.4M | XXX | -$5.4M | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | -53% | XXX | XXX | XXX |
| EBIT | -$19.1M | XXX | -$9.1M | XXX | XXX | XXX |
| EBIT Margin | -53% | XXX | -89% | XXX | XXX | XXX |
| Net Profit | -$11.8M | XXX | -$13.8M | XXX | XXX | XXX |
| Net Margin | -33% | XXX | -135% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $16.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, XOMA Royalty's stock price is $25.
XOMA Royalty has current market cap of $298M, and EV of $320M.
See XOMA Royalty trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $320M | $298M | XXX | XXX | XXX | XXX | $-1.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, XOMA Royalty has market cap of $298M and EV of $320M.
XOMA Royalty's trades at 31.3x EV/Revenue multiple, and -59.0x EV/EBITDA.
Equity research analysts estimate XOMA Royalty's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
XOMA Royalty has a P/E ratio of -25.2x.
See valuation multiples for XOMA Royalty and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $298M | XXX | $298M | XXX | XXX | XXX |
| EV (current) | $320M | XXX | $320M | XXX | XXX | XXX |
| EV/Revenue | 8.9x | XXX | 31.3x | XXX | XXX | XXX |
| EV/EBITDA | -73.5x | XXX | -59.0x | XXX | XXX | XXX |
| EV/EBIT | -16.7x | XXX | -35.3x | XXX | XXX | XXX |
| EV/Gross Profit | 8.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -25.2x | XXX | -21.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -23.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXOMA Royalty's last 12 month revenue growth is 36%
XOMA Royalty's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $1.5M for the same period.
XOMA Royalty's rule of 40 is -791% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
XOMA Royalty's rule of X is 79% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for XOMA Royalty and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 36% | XXX | 127% | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | -53% | XXX | XXX | XXX |
| EBITDA Growth | -532% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -791% | XXX | -17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 79% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 189% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
XOMA Royalty acquired XXX companies to date.
Last acquisition by XOMA Royalty was XXXXXXXX, XXXXX XXXXX XXXXXX . XOMA Royalty acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was XOMA Royalty founded? | XOMA Royalty was founded in 1981. |
| Where is XOMA Royalty headquartered? | XOMA Royalty is headquartered in United States of America. |
| How many employees does XOMA Royalty have? | As of today, XOMA Royalty has 13 employees. |
| Who is the CEO of XOMA Royalty? | XOMA Royalty's CEO is Mr. Owen P. Hughes, Jr. |
| Is XOMA Royalty publicy listed? | Yes, XOMA Royalty is a public company listed on NAS. |
| What is the stock symbol of XOMA Royalty? | XOMA Royalty trades under XOMA ticker. |
| When did XOMA Royalty go public? | XOMA Royalty went public in 1986. |
| Who are competitors of XOMA Royalty? | Similar companies to XOMA Royalty include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of XOMA Royalty? | XOMA Royalty's current market cap is $298M |
| What is the current revenue of XOMA Royalty? | XOMA Royalty's last 12 months revenue is $35.8M. |
| What is the current revenue growth of XOMA Royalty? | XOMA Royalty revenue growth (NTM/LTM) is 36%. |
| What is the current EV/Revenue multiple of XOMA Royalty? | Current revenue multiple of XOMA Royalty is 8.9x. |
| Is XOMA Royalty profitable? | Yes, XOMA Royalty is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of XOMA Royalty? | XOMA Royalty's last 12 months EBITDA is -$4.4M. |
| What is XOMA Royalty's EBITDA margin? | XOMA Royalty's last 12 months EBITDA margin is -12%. |
| What is the current EV/EBITDA multiple of XOMA Royalty? | Current EBITDA multiple of XOMA Royalty is -73.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
